Collection: Collection of Blood Research Highlights, April 16, 2020

The volume of high-start total metabolic tumors helps identify ultra-high-risk DLBCL populationshttps://doi.org/10.1182/blood.2019003526https://doi.org/10.1182/blood.2019003526early identification of patients with ultra-high-risk diffuse large B cell lymphoma (DLBCL) helps to layer innovative treatmentsPrevious studies have suggested that high-start total metabolic tumor volume (TMTV) negative lysis affected the survival prognosis of DLBCL patientsthe study analyzed the effects of TMTV and prognosticindicators on patients aged 60-80 in patients with DLBCL in the REMARC III trial (compared to nadoamine and placebo as maintenance therapy in patients treated with RCHOP)the tMTV at the start ingestpet pet/CT is calculated using the 41% SUVmax method, and the best TMTV threshold for progression-free survival (PFS) and total survival (OS) is determined using the training verification methodA total of 301 patients (155 in the indoamine group and 146 in the placebo group) were analyzed, including 192 patients classified as GCB/non-GCB and MYC/BCL2 expression groupsThe median value of the base TMTV is 238 cm3; Patients with high TMTV values (-220 cm2) showed poor/higher ECOG PS 2, STAGE III-IV disease, s1 junction, LDH elevation, IPI 3-5, and age-corrected IPI 2-3High TMTV has a significant impact on PFS and OS compared to low TMTV and has nothing to do with maintaining treatment or notAlthough GCB/non-GCB spectrum and MYC representation are independent of TMTV/survival rate, BCL2 s 70% affects PFS and can be layered through TMTVMultivariate findings starting TMTV and ECOG PS are independently related to PFS and OSEven in patients with R-CHOP postoperative response, high-start TMTV is a strong predictor of poor PFS and OSthe KIR2DS1/KIR3DL1 genotype has no predictive effect on the risk of recurrence after hematopoietic cell transplantation
https://doi.org/10.1182/blood.2019002887 several studies have shown that natural killer (NK) cell reactivity mediated by antidote immunoglobulin-like receptors reduces the risk of recurrence after hematopoietic cell transplantation (HCT) Based on a promising model, information about KIR2DS1 and KIR3DL1 and their homologous ligands can be used to classify donors into KIR-advantages or KIR-disadvantages Recently, researchers validated the model from the outside in the non-kinship donor HCT used Cox regression model to detect the effect of predictive indicators on overall survival (OS) and recurrence probability, and corrected based on patient age, corrected disease risk index, performance status, donor age, HLA-matching, gender-matching, CMV-matching, regulating chemotherapy intensity, type of T-cell depletion and type of graft A total of 2,222 AML or MDS patients were included in this analysis The KIR genotype was identified by targeting second-generation sequencing In multivariate analysis and subgroup analysis, the OS and cumulative recurrence probability of the KIR-advantage donor corresponding to the patient was comparable to that of the PATIENT with the KIR-disadvantaged donor The correction risk ratio of OS and recurrence probability was 0.99 and 1.04, respectively The researchers also tested the effects of activating donor KIR2DS1 and inhibiting KIR3DL1, respectively, but had no significant effect on OS or recurrence risk : Magnetic resonance direct thrombosis is used to detect deep vein thrombosis https://doi.org/10.1182/blood.2019004114 diagnosis of recurrent contemporaries deep vein thrombosis (DVT) can be challenging, as persistent intravascular abnormalities that have existed after DVT in the past can hinder ultrasound diagnosis Magnetic resonance direct thrombosis (MRDTI), a 10-minute acquisition technique that requires intravenous imaging, has been shown to accurately distinguish acute recurrent DVT and chronic thrombosis residues This study evaluated the safety of MRDTI as the only trial to eliminate recurrent homogenous dvT Theia Study is a forward-looking international multicenter diagnostic management study that recruits patients with clinically suspected acute recurrent homogenous DVT (NCT02262052) Patients were given MRDTI tests within 24 hours of being included in the study and managed according to the results of the MRDTI test The main result was the incidence of vein thromboembolism (VTE) within 3 months after the DVT MRDTI negative test The secondary result is the observer consistency of the MRDTI reading a total of 305 patients were included in the study The initial prevalence of recurrent DVT was 38%, and the diagnosis rate of superficial thrombosis varicosis was 4.6% Two (1.7%) of the 119 MRDTI-negative DVT and thrombosis patients (no anticoagulants were used during follow-up) developed venous thromboembolism within 3 months of the test; The recurrence rate of VTE in PATIENTs with MRDTI-negative DVT was 1.1% (95% CI 0.13-3.8%) The consistency between the initial local and post-secondary media of the MRDTI image is very good Source: MedSci Original